Furthermore, our findings are essential to designing S100A4 analogs that may possibly act as effective blockers to inhibit the RAGE V domain-S100A1 route for the treatment of many kinds of human cancer [53] and inflammation [54–57]. This evidence concerns the gene S100A4 and cancer.